Matthew Raymond Smith

Q: What Schools Are Affiliated With Matthew Raymond Smith

Matthew Raymond Smith is affiliated with the following schools: University of Liverpool, Massachusetts General Hospital

Matthew Raymond Smith's AcademicInfluence.com Rankings

Philosophy

#6116

World Rank

#9090

Historical Rank

Logic

#3304

World Rank

#4437

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Matthew Raymond Smith's Degrees

Doctorate Medicine Harvard University

Why Is Matthew Raymond Smith Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Matthew Raymond Smith's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Abiraterone in metastatic prostate cancer without previous chemotherapy. (2013) (2446)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study (2011) (1785)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. (2015) (1059)
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. (2006) (1053)
NCCN clinical practice guidelines in oncology: prostate cancer. (2010) (971)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016) (889)
Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer (2018) (824)
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. (2009) (808)
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial (2012) (728)
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. (2003) (666)
Changes in body composition during androgen deprivation therapy for prostate cancer. (2002) (649)
Adverse effects of androgen deprivation therapy and strategies to mitigate them. (2015) (562)
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. (2005) (544)
Pathologic fractures correlate with reduced survival in patients with malignant bone disease (2007) (542)
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. (2005) (511)
Insulin sensitivity during combined androgen blockade for prostate cancer. (2006) (489)
Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer (2019) (481)
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. (2005) (455)
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. (2018) (452)
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. (2010) (449)
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. (2013) (448)
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. (2010) (413)
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. (2010) (382)
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. (2010) (378)
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. (2003) (361)
Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. (2005) (346)
Metabolic complications of androgen deprivation therapy for prostate cancer. (2009) (342)
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. (2007) (325)
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. (2020) (260)
Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. (2004) (254)
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). (2014) (254)
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. (2004) (247)
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (230)
Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. (2006) (219)
Osteoporosis in men with prostate carcinoma receiving androgen‐deprivation therapy (2004) (216)
Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response (2011) (210)
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). (2014) (210)
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. (2013) (207)
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. (2008) (202)
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. (2009) (199)
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. (2016) (187)
Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. (2004) (185)
Management of Complications of Prostate Cancer Treatment (2008) (169)
Depression in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Pilot Study (2002) (163)
A Structured Exercise Program for Patients with Advanced Non-small Cell Lung Cancer (2009) (161)
Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration‐resistant nonmetastatic prostate cancer (2011) (161)
Androgen deprivation therapy for prostate cancer: new concepts and concerns (2007) (158)
Low bone mineral density in hormone‐naïve men with prostate carcinoma (2001) (156)
Non‐destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T (2001) (156)
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. (2010) (155)
Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer (2006) (155)
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. (2020) (153)
Bisphosphonates for treatment and prevention of bone metastases. (2005) (151)
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. (2017) (151)
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. (2013) (151)
Changes in bone mineral density and body composition during initial and long‐term gonadotropin‐releasing hormone agonist treatment for prostate carcinoma (2005) (147)
Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancer (2008) (143)
Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity (2008) (143)
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. (2006) (139)
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer (2019) (134)
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. (2008) (130)
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapy (2004) (130)
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. (2009) (130)
Sarcopenia during androgen-deprivation therapy for prostate cancer. (2012) (125)
Apalutamide and Overall Survival in Prostate Cancer. (2020) (124)
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. (2014) (120)
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. (2015) (118)
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. (2012) (118)
NCCN Task Force Report: Bone Health in Cancer Care. (2009) (117)
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. (2008) (116)
Metastasis and bone loss: advancing treatment and prevention. (2010) (112)
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. (2007) (109)
Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy (2004) (106)
Managing Nonmetastatic Castration-resistant Prostate Cancer. (2019) (106)
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort (2016) (102)
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. (2009) (102)
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. (2009) (100)
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. (2018) (97)
Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. (2012) (97)
Osteoporosis during androgen deprivation therapy for prostate cancer. (2002) (93)
Treatment and prevention of bone complications from prostate cancer. (2011) (92)
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. (2004) (91)
Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. (2010) (88)
Consensus on the utility of bone markers in the malignant bone disease setting. (2011) (87)
A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases (2013) (87)
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer (2010) (84)
Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. (2008) (83)
Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? (2013) (82)
Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. (2014) (79)
Androgen‐Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology (2010) (79)
Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. (2019) (78)
Obesity and mortality in men with locally advanced prostate cancer (2007) (78)
Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. (2015) (74)
Obesity and Sex Steroids during Gonadotropin-Releasing Hormone Agonist Treatment for Prostate Cancer (2007) (73)
Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. (2010) (73)
Emerging therapies to prevent skeletal morbidity in men with prostate cancer. (2011) (73)
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. (2014) (73)
Diagnosis and management of treatment‐related osteoporosis in men with prostate carcinoma (2003) (72)
Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. (2005) (70)
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events (2015) (69)
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. (2014) (69)
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302 (2016) (68)
Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. (2011) (65)
A phase II study of mifepristone (RU‐486) in castration‐resistant prostate cancer, with a correlative assessment of androgen‐related hormones (2008) (65)
Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference (2008) (65)
Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2012) (64)
A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. (2004) (63)
Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. (2014) (62)
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. (2018) (61)
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. (2007) (60)
Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer (2004) (60)
Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2012) (60)
Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. (2015) (59)
Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy (2009) (58)
Treatment-related osteoporosis in men with prostate cancer (2004) (56)
Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. (2014) (55)
Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. (2010) (55)
Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD. (2019) (55)
Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer (2018) (53)
Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients (2015) (52)
Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. (2008) (51)
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. (2015) (50)
Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. (2003) (50)
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. (2012) (50)
Estrogenic side effects of androgen deprivation therapy. (2007) (50)
Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial (2019) (49)
Bisphosphonates to Prevent Osteoporosis in Men Receiving Androgen Deprivation Therapy for Prostate Cancer (2003) (49)
Prospective Study of Changes in the Metabolomic Profiles of Men during Their First Three Months of Androgen Deprivation Therapy for Prostate Cancer (2012) (49)
Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). (2015) (45)
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer (2006) (44)
Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. (2015) (44)
New and emerging therapies for bone metastases in genitourinary cancers. (2013) (44)
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond. (2008) (44)
Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). (2020) (43)
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. (2002) (42)
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity (2009) (41)
Novel Bone-Targeted Strategies in Oncology (2010) (40)
Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. (2011) (40)
Population Pharmacokinetic Analysis of Abiraterone in Chemotherapy-Naïve and Docetaxel-Treated Patients with Metastatic Castration-Resistant Prostate Cancer (2014) (39)
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. (2015) (39)
Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). (2020) (38)
Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. (2004) (37)
Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer : Clinical and translational research in prostate cancer, part II (2002) (37)
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. (2017) (35)
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. (2022) (35)
Osteoporosis and Other Adverse Body Composition Changes during Androgen Deprivation Therapy for Prostate Cancer (2004) (35)
Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials (2013) (34)
Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. (2013) (31)
Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents (2016) (30)
Future therapies in hormone-refractory prostate cancer. (2005) (30)
Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years. (2015) (30)
Changes in body composition during hormonal therapy for prostate cancer. (2003) (30)
Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. (2003) (30)
The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). (2015) (30)
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. (2015) (29)
Advances in Treating Metastatic Bone Cancer: Summary Statement for the First Cambridge Conference (2006) (29)
Peroxisome Proliferator-Activated Receptor Gamma (PPARγ as a Novel Target for Prostate Cancer (2002) (28)
Outcomes of endoscopic human thrombin injection in the management of gastric varices (2014) (28)
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. (2005) (28)
Bone density testing among prostate cancer survivors treated with androgen‐deprivation therapy (2013) (28)
RTOG 0518: Randomized Phase III Trial to Evaluate Zoledronic Acid for Prevention of Osteoporosis and Associated Fractures in Prostate Cancer Patients (2013) (28)
Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab (2012) (28)
NCCN Task Force Report: Bone Health and Cancer Care. (2006) (27)
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer (2011) (27)
Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer. (2012) (27)
Management of treatment-related osteoporosis in men with prostate cancer. (2003) (26)
Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. (2011) (26)
Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. (2007) (25)
Use of androgen deprivation therapy for metastatic prostate cancer in older men (2008) (25)
Metabolic complications of androgen deprivation therapy for prostate cancer. (2013) (25)
Toremifene – a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy (2006) (25)
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. (2016) (24)
Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. (2003) (23)
Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC) (2008) (23)
Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. (2012) (23)
Contemporary therapeutic approaches targeting bone complications in prostate cancer. (2010) (22)
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. (2021) (22)
Therapy Insight: osteoporosis during hormone therapy for prostate cancer (2005) (22)
Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE). (2012) (22)
Mycophenolate mofetil therapy in the management of inflammatory bowel disease--a retrospective case series and review. (2014) (21)
Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP). (2015) (21)
ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC). (2018) (21)
Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention? (2011) (20)
Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting. (2015) (20)
Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. (2011) (20)
Long‐Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3‐Year Open Label Followup Results (2018) (20)
Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer (2016) (19)
Markers of bone metabolism in prostate cancer. (2006) (19)
Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. (2012) (19)
Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors (2008) (18)
Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. (2016) (18)
Bone-targeted agents: preventing skeletal complications in prostate cancer. (2012) (18)
Ostarine increases lean body mass and improves physical performance in healthy elderly subjects: Implications for cancer cachexia patients (2007) (18)
Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC) (2005) (17)
The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy. (2004) (17)
Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: An analysis of RTOG 94-08. (2012) (17)
Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer (2012) (17)
ATLAS: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy. (2016) (17)
Ra-223 experience in pretreated patients: EAP setting. (2015) (16)
Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis (2011) (16)
Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC). (2019) (16)
Ultraviolet index and racial differences in prostate cancer incidence and mortality (2013) (16)
Gonadotrophin‐releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome? (2008) (15)
Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. (2019) (15)
Antitumor activity of bisphosphonates. (2003) (15)
1091 PAIN OUTCOMES IN PATIENTS WITH BONE METASTASES FROM CASTRATE-RESISTANT PROSTATE CANCER: RESULTS FROM A PHASE 3 TRIAL OF DENOSUMAB VS. ZOLEDRONIC ACID (2011) (15)
Effective treatment for early-stage prostate cancer--possible, necessary, or both? (2011) (15)
Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer. (2012) (15)
Measurement of body fat by dual-energy X-ray absorptiometry and bioimpedance analysis in men with prostate cancer. (2002) (14)
Selective estrogen receptor modulators to prevent treatment-related osteoporosis. (2005) (14)
SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). (2018) (14)
Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. (2013) (14)
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer. (2021) (14)
Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study. (2020) (14)
Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC). (2013) (14)
Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC). (2018) (13)
Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302. (2015) (13)
Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. (2012) (13)
Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: An analysis of RTOG 94-08. (2011) (13)
Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT). (2019) (13)
ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC). (2015) (13)
Osteoclast-targeted therapy for prostate cancer (2004) (12)
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. (2013) (12)
Association between androgen deprivation therapy and fracture risk: A population-based cohort study in men with non-metastatic prostate cancer (2004) (12)
Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. (2003) (12)
Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer (2017) (12)
Gonadotropin-Releasing Hormone Agonists and the Risks of Type 2 Diabetes and Cardiovascular Disease in Men with Prostate Cancer (2011) (11)
Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study (2020) (11)
Abstract 2605: Androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study (2018) (11)
Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC). (2019) (11)
Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma. (2004) (10)
648 BENEFIT OF DENOSUMAB THERAPY IN PATIENTS WITH BONE METASTASES FROM CASTRATE RESISTANT PROSTATE CANCER: A NUMBER-NEEDED-TO-TREAT (NNT) ANALYSIS (2011) (10)
Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial. (2019) (10)
New opportunities in the management of prostate cancer–related bone complications (2009) (10)
Prostate cancer: How can we improve the health of men who receive ADT? (2009) (10)
Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. (2020) (10)
Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. (2014) (9)
Denosumab or zoledronic acid (ZA) therapy on pain interference and cancer-specific quality of life (CSQoL) in patients with castrate-resistant prostate cancer (CRPC) and bone metastases (BM). (2014) (9)
Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer. (2012) (9)
Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study (2019) (8)
ERA 223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant metastatic castration-resistant prostate cancer. (2016) (8)
Call it cancer. (2012) (8)
Prostate cancer: metastatic. (2003) (8)
A Phase II Trial of Cabozantinib in Hormone Receptor‐Positive Breast Cancer with Bone Metastases (2020) (8)
A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) versus ADT alone in nonmetastatic castration-resistant prostate cancer (M0-CRPC): The SPARTAN trial. (2014) (8)
Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors (2008) (8)
99 The impact of bone metastases on pain: Results from a phase III denosumab study in men with nonmetastatic castration-resistant prostate cancer (2013) (7)
Abstract CT129: Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN study (2019) (7)
Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer. (2013) (7)
Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and baseline (BL) comorbidities (CM). (2019) (7)
PD10-04 A POPULATION-BASED STUDY OF THE ASSOCIATION OF PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME (PSADT) WITH METASTASIS-FREE SURVIVAL (MFS) AND OVERALL SURVIVAL (OS) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS) (2018) (7)
RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis (2011) (7)
PD10-11 PROSTATE-SPECIFIC ANTIGEN (PSA) OUTCOMES IN PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) TREATED WITH APALUTAMIDE (APA): RESULTS FROM PHASE 3 SPARTAN STUDY (2018) (7)
PD11-03 RESPONSE TO APALUTAMIDE (APA) AMONG PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN BY DECIPHER GENOMIC CLASSIFIER (GC) SCORE (2019) (7)
PACLITAXEL(T), ESTRAMUSTINE(E) AND CARBOPLATIN(C) IN PATIENTS (Pts) WITH ADVANCED PROSTATE CANCER(PC): (1999) (7)
Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302). (2013) (7)
ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). (2015) (6)
Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events. (2014) (6)
ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). (2019) (6)
MP34-20 METASTASIS-FREE SURVIVAL (MFS) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS) WITH PROSTATE-SPECIFIC ANTIGEN (PSA) DECLINE TO < 0.2 NG/ML FOLLOWING APALUTAMIDE (APA) TREATMENT: POST HOC RESULTS FROM THE PHASE 3 SPARTAN STUDY (2019) (6)
Cardiovascular Mortality Following Androgen Deprivation Therapy in Men With Locally Advanced Prostate Cancer: An Analysis of RTOG 85-31 (2007) (6)
Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial. (2018) (6)
The impact of zoledronic acid treatment on frequency of skeletal complications experienced and on followup duration post diagnosis of bone metastasis in lung cancer patients (2008) (6)
A Phase II Trial of Interferon-Alpha and Toremifene in Advanced Renal Cell Cancer Patients (2002) (5)
MP34-19 EFFICACY AND SAFETY OF APALUTAMIDE (APA) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS) WITH OR WITHOUT PRIOR RADICAL PROSTATECTOMY (RP) AND/OR EXTERNAL RADIOTHERAPY (XRT): POST HOC ANALYSIS OF SPARTAN (2019) (5)
Evaluation of asymptomatic microscopic hematuria by renal ultrasound to detect upper tract malignancy: a 20-year experience in a community hospital. (2019) (5)
Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of SPARTAN. (2019) (5)
Changes in PSA kinetics after DNA vaccine therapy-not so fast! (2010) (5)
Clinical decisions. Screening for prostate cancer. (2012) (5)
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. (2021) (5)
Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN. (2020) (5)
Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial (2020) (5)
Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. (2014) (5)
Impact of concomitant bone-targeted therapies (BTT) on outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy (ctx) treated with abiraterone acetate (AA) or prednisone (P). (2013) (5)
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302 (2022) (5)
Phase 2 Study of Cabozantinib (XL184) in a Cohort of Patients With Castration-Resistant Prostate Cancer (CRPC) and Measurable Soft Tissue Disease (2011) (4)
Prevalence of osteoporosis and osteopenia during androgen deprivation (ADT) for prostate cancer: Baseline data from a large randomized controlled trial (2007) (4)
Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial. (2012) (4)
Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302. (2014) (4)
Trends in Surgical Management of Benign Prostatic Hyperplasia (2011) (4)
ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer. (2016) (4)
Prostate-specific membrane antigen positron-emission tomography (PSMA-PET) in high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC) SPARTAN-like patients (pts) negative by conventional imaging (2019) (4)
The role of bisphosphonates in the management of metastatic prostate cancer (2003) (4)
Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial. (2021) (4)
Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease (2021) (4)
711 EFFECTS OF DENOSUMAB AND ZOLEDRONIC ACID ON PAIN INTERFERENCE WITH DAILY FUNCTIONING IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER (2011) (4)
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy. (2021) (4)
Molecular determinants associated with long-term response to apalutamide (APA) in nonmetastatic castration-resistant prostate cancer (nmCRPC). (2021) (4)
Association of detectable levels of circulating tumor DNA (ctDNA) with disease burden in prostate cancer (PC). (2020) (4)
Investigator-sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases. (2012) (4)
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021 (2022) (4)
Median time to progression in chemotherapy (chemo)-naive patients with castration-resistant prostate cancer (CRPC) treated with abiraterone acetate and low-dose prednisone (Pred). (2010) (3)
Genitourinary tumors, prostate (2012) (3)
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial. (2022) (3)
Osteoporosis in men with prostate cancer: now for the fracture data. (2008) (3)
Relationship between abiraterone exposure, prostate-specific antigen (PSA) kinetics, and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) . (2014) (3)
New opportunities for the management of cancer-related bone complications. (2009) (3)
7005 Overall survival in men with and without prevalent vertebral fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer (2009) (3)
Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients. (2014) (3)
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS study. (2022) (3)
Hormonal therapies: ADT for prostate cancer: true love or heartbreak? (2010) (3)
846 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF DENOSUMAB IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY FOR NON-METASTATIC PROSTATE CANCER (2009) (3)
MP04-06 A PROSPECTIVE RANDOMIZED TRIAL OF DIETARY CARBOHYDRATE RESTRICTION FOR MEN INITIATING ANDROGEN DEPRIVATION THERAPY: CARBOHYDRATE AND PROSTATE STUDY I (CAPS1) (2016) (3)
161 DETERMINATION OF CLINICAL CHARACTERISTICS FOR MEN ON ADT AS RELATED TO BASELINE SERUM TESTOSTERONE VALUES (2011) (3)
943 PAIN INTERFERENCE WITH DAILY FUNCTIONING IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER: A COMPARISON OF DENOSUMAB AND ZOLEDRONIC ACID (2012) (3)
Efficacy and Safety Exposure–Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer (2020) (3)
Symptomatic skeletal events (SSE) in patients with advanced prostate cancer: Results from a phase III trial of denosumab for the prevention of skeletal-related events. (2014) (3)
Population pharmacokinetic analysis of abiraterone acetate in healthy volunteers and chemotherapy-naive and chemotherapy-pretreated metastatic castration-resistant prostate cancer patients. (2014) (3)
Apalutamide and Metastasis-free Survival in Prostate Cancer. (2018) (3)
Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials. (2017) (3)
7003 ORAL Denosumab and Bone Metastasis-free Survival in Men With Castrate-resistant Prostate Cancer – Subgroup Analyses From an International, Double-blind, Randomized, Phase 3 Trial (2011) (3)
1015: Phase III Interim Analysis Demonstrates Toremifene Increases Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer (2007) (2)
Urological Association: Endorsed by the American Society for Radiation Oncology Advisory From the American Heart Association, American Cancer Society, and American Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk : A Science (2013) (2)
681 DENOSUMAB DELAYS DEVELOPMENT OF MULTIPLE BONE METASTASES IN MEN WITH CASTRATE-RESISTANT PROSTATE CANCER (2012) (2)
Denosumab in men with non-metastatic castration-resistant prostate cancer (CRPC) and PSA doubling time (PSADT) <= 6 months - a post-hoc analysis of a randomised trial (2013) (2)
Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer (2016) (2)
Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies. (2020) (2)
Abstract 4133: High prevalence and heterogeneity of emergence of BRCA reversion mutations at progression on niraparib treatment in BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC) patients (2022) (2)
PD34-11 PROSTATE-SPECIFIC ANTIGEN KINETICS IN PATIENTS WITH ADVANCED PROSTATE CANCER TREATED WITH APALUTAMIDE: RESULTS FROM THE TITAN AND SPARTAN STUDIES (2021) (2)
784 THE IMPACT OF ABIRATERONE ACETATE THERAPY ON PATIENT-REPORTED PAIN AND FUNCTIONAL STATUS IN CHEMOTHERAPY-NAÏVE PATIENTS WITH PROGRESSIVE, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER - RESULTS FROM AN UPDATED ANALYSIS (2013) (2)
Androgen Deprivation and Osteoporosis (1999) (2)
ZOLEDRONIC ACID COMPARED WITH PAMIDRONATE IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASES: EFFECTS ON SKELETAL COMPLICATIONS AND BONE MARKERS (2006) (2)
Apalutamide and overall survival in patients with nonmetastatic castration-resistant prostate cancer: Updated results from the phase 3 SPARTAN study (2019) (2)
ATLAS : A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy (2016) (2)
Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. (2004) (2)
Patient (pt) reported outcomes (PROs) in SPARTAN, a phase 3, double-blind, randomized study of apalutamide (APA) plus androgen deprivation therapy (ADT) vs placebo (PBO) plus ADT in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) (2018) (2)
Treatment patterns after abiraterone acetate in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302. (2016) (2)
MP52-20 PATIENT REPORTED OUTCOMES (PROS) IN SPARTAN, A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY OF APALUTAMIDE (APA) PLUS ANDROGEN DEPRIVATION THERAPY (ADT) VS PLACEBO PLUS ADT IN MEN WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) (2018) (2)
Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: Subgroup analyses by baseline characteristics. (2014) (2)
Denosumab treatment for prolonging bone metastasis-free survival in men with castrate-resistant prostate cancer (2011) (2)
713 ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL (2013) (2)
Denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer: Results from a phase 3 randomized trial (2011) (2)
Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial. (2021) (2)
Relationship of time to metastasis (TTM) and site of metastases in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Results from the phase 3 SPARTAN trial. (2018) (2)
Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials. (2018) (2)
The science and practice of bone health in oncology (2009) (2)
Skeletal-related events in prostate cancer. (2012) (2)
A phase 3 randomized, double-blind, placebo-controlled trial of ODM-201 vs. placebo in combination with standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer (ARASENS) (2017) (2)
618P Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN (2021) (2)
C176 PROLONGED BONE METASTASIS-FREE SURVIVAL IN MEN WITH CASTRATE-RESISTANT PROSTATE CANCER RECEIVING DENOSUMAB: RESULTS FROM A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL (2011) (2)
Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial. (2021) (1)
Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer. (2014) (1)
668 Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302 (2015) (1)
Abstract A90: Efficacy and tolerability of cabozantinib at lower dose: A dose finding study in men with castration-resistant prostate cancer and bone metastases. (2011) (1)
Reply from Authors re: Ramdev Konijeti, Adam S. Kibel. Androgen Deprivation Therapy for Localized and Nonmetastatic Prostate Cancer: Too Much of a Good Thing? Eur Urol 2012;61:1129–30: Still Much to Understand About Androgen Deprivation Therapy and Cardiovascular Disease (2012) (1)
A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (MAGNITUDE). (2020) (1)
Eligibility a nd R esponse G uidelines f or P hase I I C linical Trials i n A ndrogen-Indepen dent P rostate C ancer: Recommendations F rom t he P rostate-Specifi c A ntigen Working G roup (1999) (1)
Interim safety results of a global early access protocol (EAP) of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after taxane-based chemotherapy. (2013) (1)
Foreword: skeletal complications of cancer. (2011) (1)
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide (2022) (1)
ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC). (2017) (1)
A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641). (2020) (1)
‘Tomudex’ (raltitrexed) 4.0 mg/m[2] as second- or third-line therapy in patients with advanced colorectal cancer: a Phase II study (1999) (1)
Magnetic resonance imaging and spectroscopic imaging of prostate cancer. Discussion (2003) (1)
EFFECTS OF TWICE-YEARLY SUBCUTANEOUS DENOSUMAB ON BONE MINERAL DENSITY IN MEN RECEIVING ANDROGEN-DEPRIVATION THERAPY FOR NON-METASTATIC PROSTATE CANCER (2009) (1)
Baseline N-Telopeptide Levels Correlate with Risk of Skeletal Morbidity in Patients with Multiple Myeloma during Zoledronic Acid Therapy. (2005) (1)
Survival benefits of zoledronic acid in patients with bone metastases from non-small cell lung cancer and high NTX levels: The role of BALP (2008) (1)
Rapid testosterone cycling and chemotherapy for prostate cancer: a way forward or return to the past? (2008) (1)
Cancer: ADT and acute kidney injury—causal or casual relationship? (2013) (1)
MP70-11 IMPACT OF PRIOR ENDOCRINE THERAPY ON CLINICAL BENEFIT OF ABIRATERONE ACETATE IN PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM COU-AA-302 (2014) (1)
Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis. (2015) (1)
630P Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial (2021) (1)
MP70-17 OPTIMAL TESTOSTERONE SUPPRESSION ON MEDICAL ANDROGEN DEPRIVATION THERAPY SHOULD STRIVE TO SUPPRESS FREE TESTOSTERONE LEVELS, TO LEVELS SIMILAR TO ORCHIECTOMY--WHAT IS THAT VALUE? (2014) (1)
Phase II Trial of the Antiestrogen Toremifene for Androgen‐Independent Prostate Cancer (1999) (1)
861 Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302 (2014) (1)
170 ANDROGEN DEPRIVATION THERAPY FOR NON-METASTATIC PROSTATE CANCER IS ASSOCIATED WITH AN INCREASED RISK OF PERIPHERAL ARTERIAL DISEASE AND VENOUS THROMBOEMBOLISM (2012) (1)
267: Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy and Fracture Risk in Men with Prostate Cancer (2005) (1)
MP78-01 THE BURDEN OF SKELETAL-RELATED EVENTS ON PAIN OUTCOMES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (2014) (1)
RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer (2009) (1)
A RESPONDER ANALYSIS OF THE EFFECTS OF DENOSUMAB ON BONE MINERAL DENSITY IN MEN WITH PROSTATE CANCER RECEIVING ANDROGEN DEPRIVATION THERAPY (2009) (1)
Novel Bone-targeted Strategies in Oncology Scope of the Problem Biology of Bone Disease and Metastasis (2010) (1)
Genitourinary malignancies. (2002) (1)
97 Updated interim analysis (IA): Results of randomized phase 3 study COU-AA-302 of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy (2013) (1)
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Speci ﬁ c Antigen Across Five Randomized Phase III Clinical Trials (2018) (1)
Abstract B114: Cabozantinib effects on bone metastasis: Computer-aided quantitative bone scan assessment of prostate cancer treatment response. (2011) (1)
Effect of toremifene in lowering total cholesterol, LDL, and triglycerides and raising HDL in prostate cancer patients on androgen deprivation therapy (2007) (1)
MP73-10 BONE TURNOVER MARKER LEVELS AND OUTCOMES IN MEN WITH PROSTATE CANCER AND BONE METASTASES TREATED WITH BONE ANTIRESORPTIVE AGENTS (2015) (1)
582 CARDIOVASCULAR SAFETY OF DEGARELIX: RESULTS FROM A 12-MONTH, COMPARATIVE, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP PHASE III TRIAL IN PROSTATE CANCER PATIENTS (2010) (1)
438: Fracture Risk in Men with Prostate Cancer on Androgen Deprivation Therapy (2004) (1)
Researchers The NCCN Prostate Cancer Clinical Practice Guidelines in OncologyTM (2010) (1)
Abstract CT134: Androgen receptor (AR) mutations in patients (pts) with castration-resistant prostate cancer (CRPC) with and without prior abiraterone acetate (AA) treatment (2015) (1)
556 Abiraterone acetate improves overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Impact of crossover and baseline prognostic factors in the COU-AA-302 final analysis (2015) (0)
583 TOREMIFENE IMPROVES PSA PROGRESSION FREE SURVIVAL IN CASTRATE MEN WITH DETECTABLE BASELINE PSA LEVELS (2010) (0)
Original article A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer (2004) (0)
PD14-12 SECONDARY OUTCOMES OF A PROSPECTIVE RANDOMIZED TRIAL OF DIETARY CARBOHYDRATE RESTRICTION FOR MEN INITIATING ANDROGEN DEPRIVATION THERAPY: CARBOHYDRATE AND PROSTATE STUDY I (CAPS1) (2018) (0)
Long-term efficacy and safety of enzalutamide (ENZ) monotherapy in hormone-naïve prostate cancer (HNPC): 3-year, open-label, follow-up results. (2017) (0)
Body mass index and mortality in men treated for locally advanced prostate cancer: An analysis of RTOG 85–31 (2007) (0)
Prognostic Significance of Biochemical Markers of Bone Metabolism in Patients with Bone Lesions from Multiple Myeloma (MM). (2005) (0)
108 Denosumab in men with non-metastatic castration-resistant prostate cancer (CRPC) and PSA doubling time (PSADT) ≤6 months (2013) (0)
Pathophysiology—Prostate Cancer (2013) (0)
Association of Progression by Prostate Cancer Working Group (PCWG)-2 Criteria and Survival in Metastatic Castration Resistant Prostate Cancer (2012) (0)
Reply to C. Ren et al. (2018) (0)
P79. N-Telopeptide of type I collagen (NTX) levels and prognosis in patients with bone metastases from non-small cell lung cancer (NSCLC) receiving zoledronic acid (ZOL) or placebo (2008) (0)
1822 NEED FOR INTERVENTION AND SURVIVAL IN A COHORT OF PATIENTS ON ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER (2012) (0)
Androgen deprivation therapy and acute kidney injury. (2013) (0)
Predict: Evaluation of baseline characteristics predictive of distant metastases in patients with castration-resistant prostate cancer—Updated data. (2018) (0)
Risk of Diabetes Among Patients Exposed to Primary Androgen Deprivation Therapy for Clinically Localized Prostate Cancer (2014) (0)
Prostate cancer: metastatic. (2002) (0)
National cooperative group trials. Discussion (2005) (0)
LBA01-07 OVERALL SAFETY AND INCIDENCES OF ADVERSE EVENTS BY TIME INTERVAL WITH DAROLUTAMIDE PLUS ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE PHASE 3 ARASENS TRIAL (2022) (0)
Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer. (2019) (0)
MP27-05 EFFICACY AND SAFETY OF DAROLUTAMIDE IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH AND WITHOUT PRIOR LOCAL THERAPY WITH RADICAL PROSTATECTOMY OR RADIOTHERAPY (2022) (0)
Solid tumor cancer patients treated with zoledronic acid experienced reduced skeletal related events as compared to untreated patients in clinical practice claims database (2007) (0)
Denosumab in castration-resistant prostate cancer – Authors' reply (2012) (0)
Impact of intervening in high-risk nonmetastatic castration-resistant prostate cancer (HRnmCRPC) on metastatic castration-resistant prostate cancer (mCRPC) disease burden. (2018) (0)
New treatments for patients with non‐metastatic castration‐resistant prostate cancer: A nursing perspective (2021) (0)
PD27-01 EFFICACY AND LONG-TERM SAFETY ANALYSIS OF STUDY COU-AA-302: ABIRATERONE ACETATE PLUS PREDNISONE IN CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (2014) (0)
Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022]. (2022) (0)
Prostate cancer: A personalised approach through the development of patient-derived xenografts (2016) (0)
P060 Enzalutamide monotherapy in patients with hormone-naive prostate cancer: 1-year extended follow-up of a Phase 2 study (2014) (0)
Effect of toremifene on fracture risk in men younger than age 80 on androgen-deprivation therapy. (2010) (0)
A prospective evaluation of symptom change over 4 weeks for outpatients with common solid tumors: Results from E2Z02 (the SOAPP study). (2010) (0)
Paclitaxel, E stramustine P hosphate, a nd C arboplatin i n Patients W ith A dvanced P rostate C ancer (2006) (0)
CYCLONE 1: A phase 2 study of abemaciclib in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a novel hormonal agent and taxane-based chemotherapy. (2021) (0)
Natural history of castration-resistant nonmetastatic prostate cancer: Secondary analyses of a multicenter randomized controlled trial. (2010) (0)
Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. (2022) (0)
Highlights from the 20th International Prostate Cancer Update (2010) (0)
Sunitinib, a tyrosine kinase inhibitor, produces discordant changes in 99mTc-MDP bone scans and serum PSA: A case series in prostate cancer patients (2012) (0)
718 LONG-TERM FOLLOW-UP OF A MULTICENTER PHASE II STUDY OF ABIRATERONE ACETATE (AA) + LOW-DOSE PREDNISONE (P) IN CHEMOTHERAPY-NAIVE MCRPC DEMONSTRATING RADIOGRAPHIC FLARES DISCORDANT WITH SEROLOGIC MEASURES OF RESPONSE (2011) (0)
Preventing Skeletal Complications in Prostate Cancer (2012) (0)
132 SARCOPENIA IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY (ADT) FOR PROSTATE CANCER: A PROSPECTIVE 3-YEAR STUDY (2010) (0)
Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer. (2011) (0)
Endothelin inhibition: Novel therapy for prostate cancer. Discussion (2003) (0)
304 ORAL Early normalization of elevated baseline bone resorption marker levels by zoledronic acid and improved survival in patients with bone metastases from solid tumors (2007) (0)
Optimal testosterone suppression on medical ADT should strive to suppress free testosterone levels to levels similar to orchiectomy: What is that value? (2014) (0)
SPARTAN, a phase 3 double-blind, randomized study of apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) (2018) (0)
Changes in plasma metabolomic profiles during the first 3 months of androgen-deprivation therapy for prostate cancer. (2012) (0)
Abstract B131: Efficacy and safety of darolutamide in combination with androgen-deprivation therapy (ADT) and docetaxel in Black/African-American patients from the phase 3 ARASENS trial (2023) (0)
A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC) (2004) (0)
A pilot study of an exercise program for patients with advanced non-small cell lung cancer (2008) (0)
Bisphosphonates for metastatic bone disease [mdash] too much of a good thing? (2006) (0)
869 Prevention of symptomatic skeletal events in patients with genitourinary (GU) tumours and bone metastases treated with denosumab or zoledronic acid (2014) (0)
Bone turnover marker (BTM) levels and clinical outcomes in advanced cancer patients (pts) treated with antiresorptive bone therapies. (2015) (0)
Bisphosphonates for Prevention and Treatment of Bone Metastases (2010) (0)
Re: Retrospective Evaluation Reveals that Long-Term Androgen Deprivation Therapy Improves Cause-Specific and Overall Survival in the Setting of Dose-Escalated Radiation for High-Risk Prostate Cancer (2013) (0)
Reply to F. Valcamonico et al. (2014) (0)
Curative radiation therapy for primary ocular lymphomas: Demonstration of dose response. (2010) (0)
LBA-09 DAROLUTAMIDE DELAYS PROSTATE-SPECIFIC ANTIGEN PROGRESSION AND TIME TO NEXT ANTICANCER THERAPIES IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (2019) (0)
1821 GLEASON UPGRADING AND INCREASED CANCER VOLUME ON REPEAT PROSTATE BIOPSY IN PATIENTS ON ACTIVE SURVEILLANCE (2012) (0)
– Prostate Cancer – Editor ’ s Choice Managing Nonmetastatic Castration-resistant Prostate Cancer (2019) (0)
PREDICT, a study evaluating baseline (BL) disease characteristics predictive of a positive imaging study for distant metastases in patients (pts) with castration-resistant prostate cancer (CRPC): Preliminary data. (2015) (0)
863 MULTIVARIATE ANALYSIS DEMONSTRATES TREATMENT WITH TOREMIFENE 80MG REDUCES FRACTURE RISK SIX MONTHS AFTER INITIATION OF ANDROGEN DEPRIVATION THERAPY (ADT) (2010) (0)
PF1-091ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer (2016) (0)
Risk factors for clinical fractures among men with non-metastatic prostate cancer (2005) (0)
CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer. (2020) (0)
PD17-09 PROSTATE-SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) IN HIGH-RISK NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) SPARTAN-LIKE PATIENTS (PTS) NEGATIVE BY CONVENTIONAL IMAGING (2019) (0)
Pitfalls of Androgen Deprivation Therapy (2012) (0)
Osteoporosis screening among prostate cancer survivors treated with androgen deprivation therapy. (2012) (0)
MP87-12 RADIUM-223 DICHLORIDE IN EXPANDED-ACCESS SETTING IN THE UNITED STATES: OVERALL AND CONCURRENT EXPERIENCE WITH ABIRATERONE OR ENZALUTAMIDE (2015) (0)
P061 Efficacy and safety of enzalutamide monotherapy in hormone-naive prostate cancer (HNPC) (2013) (0)
Association of alkaline phosphatase with clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): results from COU-AA-302 (2014) (0)
Diabetes and Cardiovascular Mortality in Men With Locally Advanced Prostate Cancer: Updated Analysis From RTOG 92-02 (2012) (0)
Changes in plasma metabolomic profiles during the first 3 months of androgen-deprivation therapy for prostate cancer. (2012) (0)
New androgen antagonists in non-metastatic castration-resistant prostate cancer (2019) (0)
Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in the SPARTAN and TITAN studies. (2022) (0)
Diabetes and mortality in men with locally advanced prostate cancer: analyses of RTOG 92–02 (2008) (0)
Bone metabolism biomarkers in men with advanced prostate cancer (PC) and bone metastases treated with denosumab versus zoledronic acid (ZA). (2015) (0)
A phase II trial of cabozantinib in hormone receptor-positive breast cancer with bone metastases. (2020) (0)
Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. (2016) (0)
PREDICTORS OF CLINICAL OUTCOME IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASES: PROGNOSTIC SIGNIFICANCE OF FRACTURES AND BONE MARKERS (2006) (0)
C Metabolic consequences of ADT for prostate cancer Faris and Smith 241 Sarcopenic obesity Sarcopenic obesity (2010) (0)
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen? Reply (2018) (0)
Prostate cancer (metastatic). (2003) (0)
Future therapies in hormone-refactory protate cacer. Discussion (2005) (0)
Consensus Summary FOURTH INTERNATIONAL CONFERENCE ON INNOVATIONS AND CHALLENGES IN PROSTATE CANCER: PREVENTION, DETECTION AND TREATMENT (2005) (0)
Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11] (2022) (0)
Genitourinary malignancies. (2003) (0)
1470PDecisions and supports around clinical trial participation: A national study by Cancer Trials Ireland (2017) (0)
Denosumab to Prevent Disease and Treatment-Related Skeletal Complications in Men with Prostate Cancer: Emerging Evidence (2010) (0)
Abbreviated Title: Metabolomic Changes during Adt (2012) (0)
Darolutamide in Metastatic Prostate Cancer. Reply. (2022) (0)
How quality of life can help guide selection of androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer. (2021) (0)
MP87-16 NOVEL ANTIANDROGEN ARN-509 IN HIGH-RISK NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (2015) (0)
Collaborative Review - Prostate Cancer Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks (2009) (0)
672 Prior and concurrent use of abiraterone and enzalutamide with radium-223 dichloride (Ra-223) in US expanded access setting (EAP) (2015) (0)
Checkpoint expression pre and post chemoradiation in operable esophageal cancer. (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Matthew Raymond Smith?

Matthew Raymond Smith is affiliated with the following schools:

University of Liverpool
Massachusetts General Hospital